

Learner Notification

Society of Gynecologic Oncology
2022 ACCC Series #1
Enduring: May 27, 2022 – May 27, 2023
Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Amedco LLC designates this **live activity** for a maximum of **.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of **.50 ANCC** contact hours.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of **.50** knowledge-based CPE contact hours.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives - After Attending This Program You Should Be Able To

1. The recommended clinical evaluation of patients with newly diagnosed advanced ovarian cancer.
2. The patient and disease factors that may help identify patients who are not good candidates for upfront surgery.
3. How do neoadjuvant and upfront surgery compare in regard to progression free survival, overall survival, and morbidity and mortality.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

First	Last	Disclosure
William	Burke	NA
Robert	Coleman	Abbvie: Research Grant Overall Principal Investigator, Amgen: Scientific / Medical Advisory Board Member, Clovis: Research Grant Overall Principal Investigator, Eisai: Scientific / Medical Advisory Board Member, Gsk: Scientific / Medical Advisory Board Member, Novocure: Scientific / Medical Advisory Board Member, Immunogen: Research Grant Overall Principal Investigator, Janssen: Research

		Grant Site Principal Investigator, Onxeo: Scientific / Medical Advisory Board Member, AstraZeneca: Scientific / Medical Advisory Board Member, Alkermes: Scientific / Medical Advisory Board Member, Oncomed: Scientific / Medical Advisory Board Member
Charles	Drescher	Nothing to Disclose
john	farley	Nothing to Disclose
Melissa	Hardesty	AstraZeneca-Mereck: Consultant
Jeff	Lin	C-SATS/Johnson and Johnson: Consultant
Erin	Lips	Nothing to Disclose
Sandra	Megally	Nothing to Disclose
Roisin	O'Cearbhaill	Bayer/Celgene/Juno: Scientific / Medical Advisory Board Member, Immunogen: Scientific / Medical Advisory Board Member, Fresenius Kabi: Scientific / Medical Advisory Board Member, SeaGen/Genmab: Scientific / Medical Advisory Board Member, GSK: Scientific / Medical Advisory Board Member, Regeneron: Scientific / Medical Advisory Board Member, MJH: Other, Curio Life Science: Other, Abbvie/TCR2/Atara Biotherapeutics/ GOG Foundation/StemCentryx/Regeneron/MarkerTherapeutics/Syndax/ Genmab/ Sellas Therapeutics/ Genentech: Research Grant Site Principal Investigator, Bayer/Celgene/Juno: Research Grant Overall Principal Investigator, Tesaro/GSK: Research Grant Site Principal Investigator, Ludwig Cancer Institute: Research Grant Site Principal Investigator
Aaron	Praiss	Nothing to Disclose
Tracy	Sandstrom	Nothing to Disclose
Leigha	Senter-Jamieson	Astrazeneca: Speakers Bureau, GSK: Scientific / Medical Advisory Board Member
Ashley	Stuckey	Nothing to Disclose
Premal	Thaker	Glaxo Smith Kline: Research Grant Site Principal Investigator, Glaxo Smith Kline:Scientific / Medical Advisory Board Member, Merck:Research Grant Site Principal Investigator, Merck:Scientific / Medical Advisory Board Member, Novocure: Scientific / Medical Advisory Board Member, Caris: Consultant, Astra Zeneca: Scientific / Medical Advisory Board Member, Celsion: Scientific / Medical Advisory Board Member, Celsion: Consultant, Celsion: Stock Shareholder, Eisai: Scientific / Medical Advisory Board Member, Seagen: Scientific / Medical Advisory Board Member
Todd	Tillmanns	Myriad:Scientific/Medical Advisory Board Member,Eisai:Speakers Bureau,West Cancer Center Research Institute:Employee,GSK:Speakers Bureau,Astra Zeneca:Speakers Bureau,intuitive:Speakers Bureau